Ligand-Based and Structure-Based Virtual Screening of New Sodium Glucose Cotransporter Type 2 Inhibitors

被引:1
作者
Estrada, Ana Karen [1 ]
Mendez-Alvarez, Domingo [1 ]
Juarez-Saldivar, Alfredo [1 ]
Lara-Ramirez, Edgar E. [1 ]
Martinez-Vazquez, Ana Veronica [1 ]
Villalobos-Rocha, Juan Carlos [2 ]
Palos, Isidro [3 ]
Ortiz-Perez, Eyra [1 ]
Rivera, Gildardo [1 ]
机构
[1] Inst Politecn Nacl, Lab Biotecnol Farmaceut, Ctr Biotecnol Genom, Reynosa 88710, Mexico
[2] Inst Politecn Nacl, Escuela Nacl Ciencias Biol, Dept Microbiol, Ciudad De Mexico 11340, Mexico
[3] Univ Autonoma Tamaulipas, Unidad Acad Multidisciplinaria Reynosa Rodhe, Reynosa 88779, Mexico
关键词
Diabetes mellitus; inhibitors; molecular docking; maximum common substructure; SGLT2; blood glucose; SGLT2; INHIBITOR;
D O I
10.2174/1573406419666230803122020
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background Diabetes mellitus is a metabolic disease that causes multiple complications and common comorbidities, which decreases the quality of life for people affected by the disease. Sodium glucose cotransporter type 2 (SGLT2) participates in the reabsorption of 90% of glucose in the kidneys; therefore, it is an attractive drug target for controlling blood glucose levels.Objective The aim in this work was to obtain new potential SGLT2 inhibitors.Methods A ligand-based virtual screening (LBVS) from the ZINC15, PubChem and ChemSpider databases using the maximum common substructure (MCS) scaffold was performed.Results A total of 341 compounds were obtained and analyzed by molecular docking on the active site of SGLT2. Subsequently, 15 compounds were selected for molecular dynamics (MD) simulation analysis. The compounds derived of spiroketal Sa1, Sa4, and Sa9 (<= 3.5 angstrom) in complex with the receptor SGLT2 showed good stability during 120 ns of MD.Conclusion These compounds are proposed as potential SGLT2 inhibitors.
引用
收藏
页码:1049 / 1060
页数:12
相关论文
共 41 条
[1]   Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers [J].
Abraham, Mark James ;
Murtola, Teemu ;
Schulz, Roland ;
Páll, Szilárd ;
Smith, Jeremy C. ;
Hess, Berk ;
Lindah, Erik .
SoftwareX, 2015, 1-2 :19-25
[2]   PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA [J].
Adasme, Melissa F. ;
Linnemann, Katja L. ;
Bolz, Sarah Naomi ;
Kaiser, Florian ;
Salentin, Sebastian ;
Haupt, V. Joachim ;
Schroeder, Michael .
NUCLEIC ACIDS RESEARCH, 2021, 49 (W1) :W530-W534
[3]   Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs [J].
Artasensi, Angelica ;
Pedretti, Alessandro ;
Vistoli, Giulio ;
Fumagalli, Laura .
MOLECULES, 2020, 25 (08)
[4]   ProTox-II: a webserver for the prediction of toxicity of chemicals [J].
Banerjee, Priyanka ;
Eckert, Andreas O. ;
Schrey, Anna K. ;
Preissner, Robert .
NUCLEIC ACIDS RESEARCH, 2018, 46 (W1) :W257-W263
[5]   3Drefine: an interactive web server for efficient protein structure refinement [J].
Bhattacharya, Debswapna ;
Nowotny, Jackson ;
Cao, Renzhi ;
Cheng, Jianlin .
NUCLEIC ACIDS RESEARCH, 2016, 44 (W1) :W406-W409
[6]   Integrated computational approach on sodium-glucose co-transporter 2 (SGLT2) Inhibitors for the development of novel antidiabetic agents [J].
Bhattacharya, Sushanta ;
Asati, Vivek ;
Mishra, Mitali ;
Das, Ratnesh ;
Kashaw, Varsha ;
Kashaw, Sushil Kumar .
JOURNAL OF MOLECULAR STRUCTURE, 2021, 1227 (1227)
[7]   Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management [J].
Chaudhury, Arun ;
Duvoor, Chitharanjan ;
Dendi, Vijaya Sena Reddy ;
Kraleti, Shashank ;
Chada, Aditya ;
Ravilla, Rahul ;
Marco, Asween ;
Shekhawat, Nawal Singh ;
Montales, Maria Theresa ;
Kuriakose, Kevin ;
Sasapu, Appalanaidu ;
Beebe, Alexandria ;
Patil, Naveen ;
Musham, Chaitanya K. ;
Lohani, Govinda Prasad ;
Mirza, Wasique .
FRONTIERS IN ENDOCRINOLOGY, 2017, 8
[8]   A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus [J].
Chawla, Gita ;
Chaudhary, Krishna Kr .
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2019, 13 (03) :2001-2008
[9]   Renal, metabolic and cardiovascular considerations of SGLT2 inhibition [J].
DeFronzo, Ralph A. ;
Norton, Luke ;
Abdul-Ghani, Muhammad .
NATURE REVIEWS NEPHROLOGY, 2017, 13 (01) :11-26
[10]  
DeLano W. L., 2002, PYMOL, V40, P82